The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

As of now, Halozyme’s stock has delivered a YTD performance of +36.82%, outpacing the S&P 500’s +19.62% return. This stark contrast not only showcases Halozyme’s exceptional growth but also emphasizes ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results ...

And similar to Ocrevus Zunovo in multiple sclerosis, Roche recently received FDA approval for Tecentriq Hybreza, the subcutaneous version of the PD-L1 antibody. The growth of Tecentriq has stalled ...

Although many of Roche's older drugs have seen loss of exclusivity, its PD-L1 antibody Tecentriq has been a growth driver, and we think Vabysmo can help Chugai build an ophthalmology portfolio in ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Galapagos (GLPG – Research Report) and Roche Holding AG (RHHVF – Research Report). Galapagos (GLPG ...

See Correction/Clarification at the end of this article. The Watertown biotech is already working with pharma giants Astellas Pharma Inc. and Novartis AG to engineer capsids for gene therapy delivery.

(Bloomberg) -- Roche Holding AG is willing to pay more than $1 billion to solve one of the biggest challenges of gene therapy: delivery. The Swiss drugmaker has reached a new deal with Dyno ...

Roche and GOSH DRIVE have a long standing collaborative NHS-Industry partnership in which they harnessing the power of data science to move towards more personalised care for patients. UCL Computer ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...